$USPH

Conestoga Capital Advisors’ Q2 2026 investor letter says small caps strengthened, with the Russell 2000 up and Russell 2000 Growth up 25.7% in Q2. The firm discussed U.S. Physical Therapy (NYSE:USPH), an outpatient clinic operator, and said it sold the position due to labor cost pressures, reimbursement uncertainty, and slower margin growth, despite solid rehab demand. USPH closed at $76.46 on Aug. 6, 2026.

U S PHYSICAL THERAPY INC /NV (USPH) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99 2 ex99-1.htm Exhibit 99.1 CONTACT: U.S. Physical Therapy, Inc. Jason Curtis, Interim Chief Financial Officer email: jcurtis@usph.com Chris Reading, Chief Executive Officer (713) 297-7000 Three Part Advisors Joe Noyons (817) 778-8424 USPH Reports Second Quarter 2026 Results,

U.S. Physical Therapy (NYSE: USPH) will report Q2 earnings Wednesday after the bell. The company previously reported $198.3M revenue, up 7.9% YoY, but missed EPS estimates. For the upcoming quarter, analysts expect revenue up 6.4% YoY. The article cites an average analyst price target of $93.67 versus $77.88 and notes peer results from Centene and Tenet.

Minan Peter Francis purchased 780 shares of U S PHYSICAL THERAPY INC /NV (USPH) at an average of $62.53 ($61.50–$63.14) across 2 trades over 2026-06-08 to 2026-06-09.

U.S. Physical Therapy (NYSE: USPH) reported Q1 CY2026 earnings with revenue of $198.3 million, meeting analyst expectations, but a GAAP loss of $0.12 per share, significantly missing estimates. The company's adjusted EBITDA also fell below projections, and its operating margin decreased year-over-year. Despite these challenges, the company highlighted new initiatives aimed at improving efficiency and care, expecting them to bear fruit in the latter half of the year.

Vanguard Capital Management has disclosed a 5.14% stake in US Physical Therapy Inc. (NASDAQ: USPH), holding 777,590 shares of common stock. This is reported in a Schedule 13G filing, indicating a passive investment, with Vanguard having sole dispositive power over all shares and sole voting power over 113,528 shares. The filing's impact is deemed neutral as it does not signal active intent or changes in holdings.

U.S. Physical Therapy (USPH) reported strong operating momentum in 2025, with adjusted EBITDA up 16.1% to $95 million, and expects 2026 adjusted EBITDA to be between $102 million and $106 million. The company achieved record clinic visit volumes despite Medicare rate cuts and saw significant growth in its injury prevention segment. USPH also announced two new long-term hospital affiliation agreements, projected to add at least $14 million to physical therapy revenue and $7.3 million to its adjusted EBITDA by 2027.

Harbor Capital Advisors Inc. significantly reduced its holdings in U.S. Physical Therapy, Inc. (NYSE:USPH) by 71% in the third quarter, retaining 6,401 shares valued at approximately $544,000. Despite this reduction in institutional ownership, U.S. Physical Therapy maintains a market capitalization of $1.23 billion, a P/E ratio of 34.03, and pays a quarterly dividend of $0.45. Analyst sentiment for USPH is mixed but leans positive, with an average "Moderate Buy" rating and a consensus price target of $105.33.

GRAHAM REEVE, COO at US Physical Therapy ( NYSE:USPH ) , executed a substantial insider sell on November 25, according to an SEC filing. What Happened: According to a Form 4 filing with the U.S. Securities and Exchange Commission on Tuesday, REEVE sold 743 shares of US Physical Therapy.

Investors interested in stocks from the Medical - Outpatient and Home Healthcare sector have probably already heard of Addus HomeCare ( ADUS Quick QuoteADUS - ) and U.S. Physical Therapy ( USPH Quick QuoteUSPH - ) . But which of these two stocks offers value investors a better bang for their buck ...